Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1

Conditions

Recurrence 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × tapotoclax × 1 year × Clear all
NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Amgen

Phase 1 Terminated
7 enrolled 16 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT02675452 2025-07-09

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Amgen

Phase 1 Terminated
141 enrolled 46 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡